Evaluating the Effects of Nitroglycerin on Heart Function and Urinary Output in Patients With Acute Heart Failure

Last updated: March 16, 2026
Sponsor: Copenhagen University Hospital, Hvidovre
Overall Status: Completed

Phase

4

Condition

Chest Pain

Congestive Heart Failure

Aneurysm

Treatment

Nitroglycerin (NTG)

Clinical Study ID

NCT06682260
Nitro-vers.1.1.
  • Ages > 18
  • All Genders

Study Summary

This study aims to understand how nitroglycerin affects patients with acute heart failure, a condition where the heart struggles to pump blood effectively, leading to fluid buildup and breathing difficulties. Nitroglycerin relaxes blood vessels to ease the heart's workload and may help reduce fluid buildup. The investigators hypothesize that nitroglycerin can increase blood flow from the heart and promote urine production, which may reduce congestion in AHF patients. By studying heart function, blood volume, and fluid levels during treatment, the goal is to identify which patients may benefit most from nitroglycerin therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years

  • Clinical diagnosis of AHF requiring hospitalization

  • Systolic blood pressure ≥85 mmHg

  • Echocardiographic signs of cardiac dysfunction, by at least one of

  • Left ventricular ejection fraction ≤45%

  • Abnormal left ventricular filling with dilatation of the left atrium

  • Elevated filling pressures (systolic pulmonary artery pressure>30, dilated venacava inferior or E/é>10)

  • Significant left-sided heart valve disease

Exclusion

Exclusion Criteria:

  • Ongoing ventricular taky- or brady-arrythmias or supraventricular arrhythmias withheart rate > 180 or < 40 bpm.

  • Retinopathy or intraocular lens implantation (contraindication to Valsalva maneuver)

  • Recent myocardial infarction or thromboembolic events.

  • Intake of sildenafil or vardenafil withing 24 h and tadalafil within 48 h.

  • Absolute contraindication for vasodilation using nitroglycerin as assessed bytreating physician

  • Intravenous administration of furosemide within 2 hours of baseline measurements

Study Design

Total Participants: 21
Treatment Group(s): 1
Primary Treatment: Nitroglycerin (NTG)
Phase: 4
Study Start date:
February 01, 2025
Estimated Completion Date:
November 30, 2025

Connect with a study center

  • Hvidovre Hospital

    Copenhagen,
    Denmark

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.